Medical Device User Fee Rates for Fiscal Year 2024, 48870-48878 [2023-15919]
Download as PDF
48870
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
TABLE 11—FEE SCHEDULE FOR FY
2024—Continued
Generic drug fee category
lotter on DSK11XQN23PROD with NOTICES1
Active Pharmaceutical Ingredient (API)—Domestic ...................................
API—Foreign .....................
Finished Dosage Form
(FDF)—Domestic ...........
FDF—Foreign ....................
Contract Manufacturing Organization (CMO)—Domestic .............................
CMO—Foreign ..................
GDUFA Program
Large size operation generic drug applicant .......
Medium size operation generic drug applicant .......
Small business generic
drug applicant ................
Fees rates
for FY 2024
40,464
55,464
220,427
235,427
52,902
67,902
1,729,629
691,852
172,963
‘‘Pay Now’’ should be selected to be
redirected to Pay.gov. Electronic
payment options are based on the
balance due. Payment by credit card is
available for balances less than $25,000.
If the balance exceeds this amount, only
the ACH option is available. Payments
must be made using U.S. bank accounts
as well as U.S. credit cards.
If a check, bank draft, or postal money
order is submitted, make it payable to
the order of the Food and Drug
Administration and include the user fee
ID number to ensure that the payment
is applied to the correct fee(s). Payments
can be mailed to: Food and Drug
Administration, P.O. Box 979108, St.
Louis, MO 63197–9000. If checks are to
be sent by a courier that requests a street
address, the courier can deliver checks
to U.S. Bank, Attention: Government
Lockbox 979108, 1005 Convention
Plaza, St. Louis, MO 63101. (Note: This
U.S. Bank address is for courier delivery
only. For questions concerning courier
delivery, U.S. Bank can be contacted at
314–418–4013. This telephone number
is only for questions about courier
delivery.) The FDA post office box
number (P.O. Box 979108) must be
written on the check, bank draft, or
postal money order.
For payments made by wire transfer,
include the unique user fee ID number
to ensure that the payment is applied to
the correct fee(s). Without the unique
user fee ID number, the payment may
not be applied. If the payment amount
is not applied, the invoice amount will
be referred to collections. The
originating financial institution may
charge a wire transfer fee. Include
applicable wire transfer fees with
payment to ensure fees are fully paid.
Questions about wire transfer fees
should be addressed to the financial
institution. The following account
information should be used to send
payments by wire transfer: U.S.
Department of the Treasury, TREAS
NYC, 33 Liberty St., New York, NY
10045, account number: 75060099,
routing number: 021030004, SWIFT:
FRNYUS33. FDA’s tax identification
number is 53–0196965.
X. Fee Payment Options and
Procedures
The new fee rates are effective on
October 1, 2023, and will remain in
effect through September 30, 2024.
Under sections 744B(a)(4) and (5) of the
FD&C Act, respectively, facility and
program fees are generally due on the
later of the first business day on or after
October 1 of each fiscal year or the first
business day after the enactment of an
appropriations act providing for the
collection and obligation of GDUFA fees
for the fiscal year.
To pay the ANDA, DMF, API facility,
FDF facility, CMO facility, and GDUFA
program fees, complete the Generic
Drug User Fee Cover Sheet, available at
https://www.fda.gov/gdufa and https://
userfees.fda.gov/OA_HTML/
gdufaCAcdLogin.jsp, and generate a user
fee identification (ID) number. Payment
must be made in U.S. currency drawn
on a U.S. bank by electronic check,
check, bank draft, U.S. postal money
order, credit card, or wire transfer. The
preferred payment method is online
using electronic check (Automated
Clearing House (ACH), also known as
eCheck) or credit card (Discover, VISA,
MasterCard, American Express). FDA
has partnered with the U.S. Department
of the Treasury to utilize Pay.gov, a webbased payment application, for online
electronic payment. The Pay.gov feature
Dated: July 25, 2023.
is available on the FDA website after
completing the Generic Drug User Fee
Lauren K. Roth,
Cover Sheet and generating the user fee
Associate Commissioner for Policy.
ID number.
[FR Doc. 2023–16081 Filed 7–27–23; 8:45 am]
Secure electronic payments can be
BILLING CODE 4164–01–P
submitted using the User Fees Payment
Portal at https://userfees.fda.gov/pay.
(Note: Only full payments are accepted;
no partial payments can be made
online.) Once an invoice is located,
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–2965]
Medical Device User Fee Rates for
Fiscal Year 2024
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
fee rates and payment procedures for
medical device user fees for fiscal year
(FY) 2024. The Federal Food, Drug, and
Cosmetic Act (FD&C Act), as amended
by the Medical Device User Fee
Amendments of 2022 (MDUFA V),
authorizes FDA to collect user fees for
certain medical device submissions and
annual fees both for certain periodic
reports and for establishments subject to
registration. This notice establishes the
fee rates for FY 2024, which apply from
October 1, 2023, through September 30,
2024, and provides information on how
the fees for FY 2024 were determined,
the payment procedures you should
follow, and how you may qualify for
reduced small business fees.
FOR FURTHER INFORMATION CONTACT:
For information on Medical Device
User Fees: https://www.fda.gov/
industry/fda-user-fee-programs/
medical-device-user-fee-amendmentsmdufa.
For questions relating to the MDUFA
Small Business Program, please visit the
Center for Devices and Radiological
Health’s website: https://www.fda.gov/
medical-devices/premarketsubmissions/reduced-medical-deviceuser-fees-small-business-determinationsbd-program.
For questions relating to this notice:
Olufunmilayo Ariyo, Office of Financial
Management, Food and Drug
Administration, 4041 Powder Mill Rd.,
Beltsville, MD 20705–4304, 240–402–
4989; or the User Fee Support Staff at
OO-OFBAP-OFM-UFFS-Government@
fda.hhs.gov.
SUMMARY:
SUPPLEMENTARY INFORMATION:
I. Background
The FD&C Act, as amended by
MDUFA V, authorizes FDA to collect
user fees for certain medical device
submissions and annual fees both for
certain periodic reports and for
establishments subject to registration.
Section 738 of the FD&C Act (21 U.S.C.
379j) establishes fees for certain medical
device applications, submissions,
supplements, notices, and requests (for
E:\FR\FM\28JYN1.SGM
28JYN1
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
simplicity, this document refers to these
collectively as ‘‘submissions’’ or
‘‘applications’’); for periodic reporting
on class III devices; and for the
registration of certain establishments.
Under the FD&C Act, the fee rate for
each type of submission is set at a
specified percentage of the standard fee
for a premarket application (a premarket
application is a premarket approval
application (PMA), a product
development protocol (PDP), or a
biologics license application (BLA)).
The FD&C Act specifies the base fee for
a premarket application for each year
from FY 2023 through FY 2027; the base
fee for a premarket application received
by FDA during FY 2024 is $435,000.
From this starting point, this document
establishes FY 2024 fee rates for certain
types of submissions, and for periodic
reporting, by applying criteria specified
in the FD&C Act. Under statutorily
defined conditions, a qualified
applicant may receive a fee waiver or
may pay a lower small business fee (see
21 U.S.C. 379j(d) and (e)). For more
information on fee waivers, please see
Section IX. Small Business Fee
Reductions and Fee Waivers.
The FD&C Act specifies the base fee
for establishment registration for each
year from FY 2023 through FY 2027; the
base fee for an establishment
registration in FY 2024 is $6,875. Each
establishment that is registered (or is
required to register) with the Secretary
of Health and Human Services under
section 510 of the FD&C Act (21 U.S.C.
360) because such establishment is
engaged in the manufacture,
preparation, propagation, compounding,
or processing of a device is required to
pay the annual fee for establishment
registration.
II. Total Revenue Amount for FY 2024
The total revenue amount for FY 2024
is $335,750,000, as set forth in the
statute prior to the inflation adjustment
(see 21 U.S.C. 379j(b)(3)). MDUFA V
directs FDA to use the yearly total
revenue amount as a starting point to set
the standard fee rates for each fee type.
The fee calculations for FY 2024 are
described in this document.
48871
Inflation Adjustment
MDUFA specifies that the
$335,750,000 is to be adjusted for
inflation increases for FY 2024 using
two separate adjustments: one for
payroll costs and one for non-payroll
costs (see 21 U.S.C. 379j(c)(2)). The base
inflation adjustment for FY 2024 is the
sum of one plus the two separate
adjustments and is compounded as
specified in the statute (see 21 U.S.C.
379j(c)(2)(C) and 379j(c)(2)(B)).
The component of the inflation
adjustment for payroll costs is the
average annual percent change in the
cost of all personnel compensation and
benefits (PC&B) paid per full-time
equivalent position (FTE) at FDA for the
first 3 of the 4 preceding FYs,
multiplied by 0.60, or 60 percent (see 21
U.S.C. 379j(c)(2)(C)).
Table 1 summarizes the actual cost
and FTE data for the specified FYs,
provides the percent change from the
previous fiscal year, and provides the
average percent change over the first 3
of the 4 fiscal years preceding FY 2024.
The 3-year average is 3.9280 percent
(rounded).
TABLE 1—FDA PC&Bs EACH YEAR AND PERCENT CHANGE
FY 2020
Total PC&B ......................................................................................
Total FTE .........................................................................................
PC&B per FTE .................................................................................
Percent change from previous year ................................................
The payroll adjustment is 3.9280
percent multiplied by 60 percent, or
2.3568 percent. The statute specifies
that the component of the inflation
adjustment for non-payroll costs for FY
2024 is the average annual percent
change that occurred in the Consumer
Price Index (CPI) for urban consumers
FY 2021
$2,875,592,000
$17,535
$163,922
7.3063%
FY 2022
$3,039,513,000
$18,501
$164,289
0.1811%
(Washington-Arlington-Alexandria, DCVA-MD-WV; Not Seasonally Adjusted;
All Items; Annual Index) for the first 3
of the preceding 4 years of available
data multiplied by 0.40, or 40 percent
(see 21 U.S.C. 379j(c)(2)(C)).
Table 2 provides the summary data
and the 3-year average percent change
in the specified CPI for the Washington-
$3,165,477,000
$18,474
$171,348
4.2967%
3-Year average
............................
............................
............................
3.9280%
Arlington-Alexandria area. These data
are published by the Bureau of Labor
Statistics and can be found on their
website under series Id CUURS35ASA0
at: https://data.bls.gov/pdq/
SurveyOutputServlet?data_
tool=dropmap&series_
id=CUURS35ASA0,CUUSS35ASA0.
TABLE 2—ANNUAL AND 3-YEAR AVERAGE PERCENT CHANGE IN WASHINGTON-ARLINGTON-ALEXANDRIA AREA CPI
lotter on DSK11XQN23PROD with NOTICES1
Annual CPI .......................................................................................
Annual Percent Change ..................................................................
3-Year Average Percent Change in CPI .........................................
The non-payroll adjustment is 3.8256
percent multiplied by 40 percent, or
1.5302 percent. Next, the payroll
adjustment (2.3568 percent or 0.023568)
is added to the non-payroll adjustment
(1.5302 percent or .015302), for a total
of 3.8870 percent (or 0.038870). To
complete the inflation adjustment, 1
(100 percent or 1.0) is added for a total
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
2020
2021
2022
3-Year average
267.157
0.8989%
............................
277.728
3.9568%
............................
296.117
6.6212%
............................
............................
............................
3.8256%
base inflation adjustment of 1.03887 for
FY 2024.
MDUFA V provides for this inflation
adjustment to be compounded for FY
2023 and each subsequent fiscal year
(see 21 U.S.C. 379j(c)(2)(B)(ii)). To
complete the compounded inflation
adjustment for FY 2024, the FY 2023
compounded adjustment (1.038870) is
multiplied by the FY 2024 base inflation
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
adjustment (1.038935) to reach the
applicable inflation adjustment of
1.079318 (rounded) for FY 2024. We
then multiply the total revenue amount
for FY 2024 ($335,750,000) by 1.079318,
yielding an inflation adjusted total
revenue amount of $362,381,000
(rounded to the nearest thousand
dollars).
E:\FR\FM\28JYN1.SGM
28JYN1
48872
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
III. Adjustments to Base Fee Amounts
for FY 2024
Under the FD&C Act, all submission
fees and the periodic reporting fee are
set as a percent of the standard (full) fee
for a premarket application (see 21
U.S.C. 379j(a)(2)(A)).
A. Inflation Adjustment
MDUFA specifies that the base fees of
$435,000 (premarket application) and
$6,875 (establishment registration) are
to be adjusted for FY 2024 using the
same methodology as that for the total
revenue inflation adjustment in section
II (see 21 U.S.C. 379j(c)(2)(D)(i)).
Multiplying the base fees by the
compounded inflation adjustment of
1.079318 yields inflation adjusted base
fees of $469,503 (premarket application)
and $7,420 (establishment registration).
B. Further Adjustments To Generate the
Inflation-Adjusted Total Revenue
Amount
After the applicable inflation
adjustment to fees is done, FDA may
increase, if necessary to achieve the
inflation adjusted total revenue amount,
the base fee amounts on a uniform
proportionate basis (see 21 U.S.C.
379j(c)(2)(D)(ii)). After this adjustment,
if necessary, FDA may further increase
the base establishment registration fees
to generate the inflation-adjusted total
revenue amount (see 21 U.S.C.
379j(c)(3)).
lotter on DSK11XQN23PROD with NOTICES1
C. MDUFA V Adjustments Solely to
Registration Fees
MDUFA V has three new potential
adjustments that will not change the
total revenue amount but may impact
collections by increasing or decreasing
establishment registration base fees
only. These adjustments are the
performance improvement adjustment,
the hiring adjustment, and the operating
reserve adjustment. Only the operating
reserve adjustment is potentially
applicable in FY 2024.
1. Performance Improvement
Adjustment
For FY 2024, there is no performance
improvement adjustment. Beginning
with FY 2025, this adjustment allows
FDA to collect fees in addition to the
total revenue amount in FYs 2025, 2026,
and 2027, if the Agency meets certain
performance goals in FYs 2023, 2024,
and 2025. If applicable, this provision
further increases base establishment
registration fee amounts to achieve an
increase in total fee collections equal to
the applicable performance
improvement adjustment, which is set
forth in the statute (see 21 U.S.C.
379j(c)(4)).
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
2. Hiring Adjustment
For FY 2024, there is no hiring
adjustment. Beginning with FY 2025,
this adjustment provides for the
reduction of base establishment
registration fees in FYs 2025, 2026, and
2027, if specified hiring goals for FYs
2023, 2024, and 2025 are not met by a
certain threshold. The hiring adjustment
would serve to decrease the base
establishment registration fee amounts
as necessary to achieve a reduction in
total fee collections equal to the hiring
adjustment amount, which is set forth in
the statute (see 21 U.S.C. 379j(c)(5)).
3. Operating Reserve Adjustment
For FYs 2023 to 2027, the operating
reserve adjustment requires FDA to
decrease base establishment registration
fees if the amount of operating reserves
of carryover user fees exceeds the
‘‘designated amount’’ and such
reduction is necessary to provide for not
more than such designated amount of
operating reserves of carryover user fees
(see 21 U.S.C. 379j(c)(6)). In making this
calculation for FYs 2023 to 2026, a
certain amount is excluded from the
designated amount and is not subject to
the decrease (see 21 U.S.C.
379j(c)(6)(C)). For FY 2024, this
excluded amount is $100,600,981.
The designated amount is equal to the
sum of 13 weeks of operating reserves
of carryover user fees plus 1 month of
operating reserves described in 21
U.S.C. 379j(c)(8) (see 21 U.S.C.
379j(c)(6)(B)).
To determine the 13-week operating
reserves of carryover user fees amount,
the FY 2024 inflation-adjusted total
revenue amount, $362,381,000 is
divided by 52, and then multiplied by
13. The 13-week operating reserve
amount for FY 2024 is $90,595,250.
To determine the 1 month of
operating reserves described in 21
U.S.C. 379j(c)(8), the FY 2024 inflationadjusted total revenue amount of
$362,381,000 is divided by 12. The 1
month of operating reserves for FY 2024
is $30,198,417.
For FY 2024, the designated amount
is equal to the 13-week operating
reserve of $90,595,250 plus the 1 month
of operating reserves of $30,198,417,
totaling $120,793,667.
To determine the FY 2023 end-of-year
operating reserves of carryover user fees
amount, FDA combined the actual
collections and obligations at the end of
the third quarter (June 2023) and added
the forecasted collections and
obligations for the fourth quarter of FY
2023 to generate a full year estimate for
FY 2023. The estimated end-of-year FY
2023 operating reserves of carryover
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
user fees is $30,019,132. (Note, this
amount includes the 1-month reserve.)
Note that under MDUFA V, for the
purposes of calculating the operating
reserve adjustment, this amount does
not include user fee funds considered
unappropriated ($26,680,243) or
unearned revenue ($65,418,275). In
addition, as noted above, for purposes of
the operating reserve adjustment,
operating reserves of carryover user fees
do not include the estimated
$100,600,981 remaining to spend at the
end of FY 2023 from the total of
$118,000,000 intended to support the
Total Product Life Cycle Advisory
Program Pilot and Third-Party Review
programs.
Because the estimated end-of-year FY
2023 MDUFA operating reserves of
carryover user fees amount totaling
$30,019,132 does not exceed the FY
2024 designated amount of
$120,793,667 FDA will not decrease the
base establishment registration fee
amounts for FY 2024 to provide for not
more than such designated amount.
IV. Calculation of Fee Rates
As noted in section II, the total
revenue amount after the applicable
inflation adjustment is $362,381,000
(rounded to the nearest thousand
dollar). As noted in section III, there is
no MDUFA V adjustment solely to
registration fees for FY 2024.
Table 3A provides fee-paying
submission counts excluding
establishment registration for the last 3
years and the 3-year average. Table 3B
provides establishment registration feepaying submission counts for the last 5
years and the 5-year average.
Historically, FDA has estimated the total
number of fee-paying submission counts
it expects to receive during the next
fiscal year by averaging the number of
fee-paying submission counts received
in the 3 most recently completed fiscal
years; for FY 2024 fee-setting, this
would be an average of FY 2020 through
FY 2022. FDA received an abnormally
high volume of fee paying establishment
registrations due to the COVID–19
pandemic in FY 2020 and FY 2021. The
surge in fee-paying establishment
registrations has been declining starting
in FY 2022, trending back toward prepandemic levels. In an effort to
normalize the projected volume of
establishment registration submissions
for the FY 2024 fee-setting calculation
and more accurately project the
associated establishment registration
revenue, FDA decided to average the
number of establishment registrations
from FY 2018 through FY 2022. FDA
believes a 5-year average to estimate
establishment registration volume will
E:\FR\FM\28JYN1.SGM
28JYN1
48873
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
minimize the impact of the surge in fee
paying establishment registration
volume in FY 2020 and FY 2021.
TABLE 3A—THREE-YEAR AVERAGE OF FEE-PAYING SUBMISSIONS (EXCLUDING ESTABLISHMENT REGISTRATION)
FY 2020
actual
Application type
Full Fee applications ....................................................................................
Small Business .....................................................................................
Panel-Track Supplements ...........................................................................
Small Business .....................................................................................
De Novo Classifications ...............................................................................
Small Business .....................................................................................
180-Day Supplements .................................................................................
Small Business .....................................................................................
Real-Time Supplements ..............................................................................
Small Business .....................................................................................
510(k)s .........................................................................................................
Small Business .....................................................................................
30-Day Notice (Note also includes counts for 135 Day Supplements) .......
Small Business .....................................................................................
513(g)(21 U.S.C. 360c(g)) Request for Classification Information ..............
Small Business .....................................................................................
Annual Fee for Periodic Reporting ..............................................................
Small Business .....................................................................................
FY 2021
actual
29
7
23
6
20
47
124
20
175
28
2,048
1,667
870
104
96
57
622
95
FY 2022
actual
25
5
31
6
16
42
98
34
150
20
2,133
1,846
843
77
83
53
613
84
3-Year average
18
3
21
1
23
53
93
31
140
12
2,012
1,757
782
67
93
58
620
87
24
5
25
4
20
47
105
28
155
20
2,064
1,757
832
83
91
56
618
89
TABLE 3B—FIVE-YEAR AVERAGE OF FEE-PAYING ESTABLISHMENT REGISTRATION SUBMISSIONS
Application type
FY 2018
FY 2019
FY 2020
FY 2021
FY 2022
5-Year average
Establishment Registrations ..............................................
27,544
27,728
41,942
33,812
31,748
32,555
The information in tables 3A and 3B
is necessary to estimate the amount of
revenue that will be collected based on
the fee amounts. Tables 4A and B
display the FY 2024 base fees set in
statute (column one) and the inflation
adjusted base fees (per calculations in
section III.A.) (column two). Using the
inflation adjusted fees, the 3-year
average of fee-paying submissions
(excluding establishment registration),
and the 5-year average of fee-paying
establishment registration submissions,
collections are projected to total
$351,531,781 which is $10,849,219
lower than the inflation adjusted total
revenue amount (in section II).
Accordingly, the next step in the fee
setting process is to increase the base fee
amounts on a uniform proportionate
basis to generate the inflation adjusted
total revenue amounts (see 21 U.S.C.
379j(c)(2)(D)(ii) and table 4A, column
three).
Applying these further adjusted fee
rates to the 3-year average of fee paying
submissions, and the 5-year average of
fee-paying establishment registration
submissions results in estimated total
fee collections of $362,040,886, which is
still $340,114 lower than the inflation
adjusted total revenue amount (in
Section II). The next step in the fee
setting process, after the adjustment in
(2)(D) is done, is to increase the base
establishment registration fee amount as
necessary for total fee collections to
generate the inflation adjusted total
revenue amount, as adjusted under
paragraph (2) (see 21 U.S.C. 379j(c)(3)).
Accordingly, the base establishment
registration fee was increased by $11 for
an establishment registration fee rate of
$7,653 (see 21 U.S.C. 379j(c)(3)). The
fees in column three in tables 4A and 4B
are those we are establishing for FY
2024, which are the standard fees.
TABLE 4A—FEES NEEDED TO ACHIEVE NEW FY 2024 REVENUE TARGET
FY 2024
statutory
fees
(base fees)
lotter on DSK11XQN23PROD with NOTICES1
Application type
Full Fee Applications ...................................................
Small Business .....................................................
Panel-Track Supplement .............................................
Small Business .....................................................
De Novo Classification Request ..................................
Small Business .....................................................
180-Day Supplements .................................................
Small Business .....................................................
Real-Time Supplements ..............................................
Small Business .....................................................
510(k)s .........................................................................
Small Business .....................................................
30-Day Notice ..............................................................
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
PO 00000
$435,000
108,750
348,000
87,000
130,500
32,625
65,250
16,313
30,450
7,613
19,575
4,894
6,960
Frm 00088
Fmt 4703
FY 2024
inflation
adjusted
statutory
base fees
(standard fees)
$469,503
117,376
375,603
93,901
140,851
35,213
70,425
17,606
32,865
8,216
21,128
5,282
7,512
Sfmt 4703
Adjusted
FY 2024
fees to meet
revenue
target
(standard fees)
$483,560
120,890
386,848
96,712
145,068
36,267
72,534
18,134
33,849
8,462
21,760
5,440
7,737
E:\FR\FM\28JYN1.SGM
28JYN1
3-Year
average of
fee-paying
submissions
24
5
25
4
20
47
105
28
155
20
2,064
1,757
832
FY 2024
revenue from
adjusted fees
$11,605,440
604,450
9,671,200
386,848
2,901,360
1,704,549
7,616,070
507,752
5,246,595
169,240
44,912,640
9,558,080
6,437,184
48874
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
TABLE 4A—FEES NEEDED TO ACHIEVE NEW FY 2024 REVENUE TARGET—Continued
FY 2024
statutory
fees
(base fees)
Application type
FY 2024
inflation
adjusted
statutory
base fees
(standard fees)
Adjusted
FY 2024
fees to meet
revenue
target
(standard fees)
3-Year
average of
fee-paying
submissions
FY 2024
revenue from
adjusted fees
Small Business .....................................................
513(g) Request for Classification Information .............
Small Business .....................................................
Annual Fee for Periodic Reporting ..............................
Small Business .....................................................
3,480
5,873
2,937
15,225
3,806
3,756
6,338
3,169
16,433
4,108
3,869
6,528
3,264
16,925
4,231
83
91
56
618
89
321,127
594,048
182,784
10,459,650
376,559
Total ...............................................................
........................
............................
............................
........................
113,255,576
TABLE 4B—FEES NEEDED TO ACHIEVE NEW FY 2024 REVENUE TARGET
Application type
FY 2024
statutory
fees
(base fees)
FY 2024
inflation
adjusted
statutory
base fees
(standard fees)
Adjusted
FY 2024 fees
to meet
revenue
target
(standard fees)
5-Year
average of
fee-paying
submissions
FY 2024
revenue from
adjusted fees
Establishment Registrations ........................................
$6,875
$7,420
$7,653
32,555
$249,143,415
The standard fee (adjusted base
amount) for a premarket application,
including a BLA, and for a premarket
report and a BLA efficacy supplement,
is $483,560 for FY 2024. The fees set by
reference to the standard fee for a
premarket application are:
• For a panel-track supplement, 80
percent of the standard fee;
• For a de novo classification request,
30 percent of the standard fee;
• For a 180-day supplement, 15
percent of the standard fee;
• For a real-time supplement, 7
percent of the standard fee;
• For an annual fee for periodic
reporting concerning a class III device,
3.5 percent of the standard fee;
• For a 510(k) premarket notification,
4.5 percent of the standard fee;
• For a 30-day notice, 1.6 percent of
the standard fee; and
• For a 513(g) request for
classification information, 1.35 percent
of the standard fee.
For all submissions other than a 30day notice and a 513(g) request for
classification information, the small
business fee is 25 percent of the
standard (full) fee for the submission
(see 21 U.S.C. 379j(d)(2)(C) and
(e)(2)(C)). For a 30-day notice and a
513(g) request for classification
information, the small business fee is 50
percent of the standard (full) fee for the
submission (see 21 U.S.C. 379j(d)(2)(C)).
The annual fee for establishment
registration, after adjustments, is set at
$7,653 for FY 2024. For FY 2024, there
is no small business waiver for the
annual establishment registration fee; all
establishments pay the same fee.
For more information on reduced fees
and waivers for small businesses, please
see Section IX. Small Business Fee
Reductions and Fee Waivers.
Table 5 summarizes the FY 2024 rates
for all medical device fees.
TABLE 5—MEDICAL DEVICE FEES FOR FY 2024
Standard fee
(as a percent of the
standard fee for a
premarket application)
lotter on DSK11XQN23PROD with NOTICES1
Application fee type
Premarket application (a PMA submitted under section 515(c)(1) of the FD&C Act (21
U.S.C. 360e(c)(1)), a PDP submitted under section 515(f) of the FD&C Act, or a
BLA submitted under section 351 of the Public Health Service Act (the PHS Act)
(42 U.S.C. 262)).
Premarket report (submitted under section 515(c)(2) of the FD&C Act) ........................
Efficacy supplement (to an approved BLA under section 351 of the PHS Act) .............
Panel-track supplement ...................................................................................................
De novo classification request .........................................................................................
180-day supplement ........................................................................................................
Real-time supplement ......................................................................................................
510(k) premarket notification submission ........................................................................
30-day notice ...................................................................................................................
513(g) request for classification information ...................................................................
Annual Fee Type .............................................................................................................
Annual fee for periodic reporting on a class III device ...................................................
Annual establishment registration fee (to be paid by the establishment engaged in the
manufacture, preparation, propagation, compounding, or processing of a device, as
defined by 21 U.S.C. 379i(14)).
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Base fee specified in
statute.
100 ............................
100 ............................
80 ..............................
30 ..............................
15 ..............................
7 ................................
4.5 .............................
1.60 ...........................
1.35 ...........................
....................................
3.50 ...........................
Base fee specified in
statute.
E:\FR\FM\28JYN1.SGM
28JYN1
FY 2024
standard fee
FY 2024
small
business fee
$483,560
$120,890
483,560
483,560
386,848
145,068
72,534
33,849
21,760
7,737
6,528
........................
16,925
7,653
120,890
120,890
96,712
36,267
18,134
8,462
5,440
3,869
3,264
........................
4,231
7,653
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
lotter on DSK11XQN23PROD with NOTICES1
V. How To Qualify as a Small Business
for Purposes of Medical Device Fees
If your business, including your
affiliates, has gross receipts or sales of
no more than $100 million for the most
recent tax year, you may qualify for
reduced small business fees. If your
business, including your affiliates, has
gross sales or receipts of no more than
$30 million, you may also qualify for a
waiver of the fee for your first premarket
application (i.e., PMA, PDP, or BLA) or
premarket report. If you want to pay the
small business fee rate for a submission
or you want to receive a waiver of the
fee for your first premarket application
or premarket report, you must submit
the materials showing you qualify as a
small business at least 60 days before
you send your submission to FDA. For
more information on fee waivers or
reductions, please see Section IX. Small
Business Fee Reductions and Fee
Waivers.
Please note that the establishment
registration fee is not eligible for a
reduced small business fee. As a result,
if the establishment registration fee is
the only medical device user fee that
you will pay in FY 2024, you should not
submit a Small Business Certification
Request. FDA will review your
information and determine whether you
qualify as a small business eligible for
the reduced fee and/or fee waiver. If you
make a submission before FDA finds
that you qualify as a small business, you
must pay the standard (full) fee for that
submission.
If your business qualified as a small
business for FY 2023, your status as a
small business will expire at the close
of business on September 30, 2023. You
must re-qualify for FY 2024 in order to
pay small business fees during FY 2024.
A. Domestic (U.S.) Businesses
If you are a domestic (U.S.) business
and wish to qualify as a small business
for FY 2024, submit the following to
FDA:
1. A completed MDUFA Small
Business Certification Request for a
Business Headquartered in the United
States (Form FDA 3602). Form FDA
3602 is provided in the FDA Forms
database: https://www.fda.gov/media/
128050/download.
2. A signed copy of your Federal
(U.S.) Income Tax Return for the most
recent tax year. The most recent tax year
will be 2023, except:
• If you submit your MDUFA Small
Business Certification Request for FY
2024 before April 15, 2024, and you
have not yet filed your return for 2023,
you may use tax year 2022.
• If you submit your MDUFA Small
Business Certification Request for FY
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
2024 on or after April 15, 2024, and
have not yet filed your 2023 return
because you obtained an extension, you
may submit your most recent return
filed prior to the extension.
3. For each of your affiliates, either:
• If the affiliate is a domestic (U.S.)
business, a signed copy of the affiliate’s
Federal (U.S.) Income Tax Return for the
most recent tax year, or
• If the affiliate is a foreign business
and cannot submit a Federal (U.S.)
Income Tax Return, a National Taxing
Authority Certification completed by,
and bearing the official seal of, the
National Taxing Authority, if extant, of
the country in which the firm is
headquartered. The National Taxing
Authority is the foreign equivalent of
the U.S. Internal Revenue Service. This
certification must show the amount of
gross receipts or sales for the most
recent tax year, in both U.S. dollars and
the local currency of the country, the
exchange rate used in converting the
local currency to U.S. dollars, and the
dates of the gross receipts or sales
collected. The business must also
submit a statement signed by the head
of the business’s firm or by its chief
financial officer that the business has
submitted certifications for all of its
affiliates, identifying the name of each
affiliate, or that the business has no
affiliates.
• If your affiliate is headquartered in
a country without a National Taxing
Authority, please contact the Division of
Industry and Consumer Education at
800–638–2041 or 301–796–7100 or
email at DICE@fda.hhs.gov.
4. Once you have completed your
Form FDA 3602, print and sign the
form. Mail the completed form and your
supporting documentation (copies of the
Federal (U.S.) income tax returns) to
Medical Device User Fee Small Business
Certification Request mailing address,
which is available at the following
website: https://www.fda.gov/
MedicalDevices/DeviceRegulation
andGuidance/HowtoMarketYourDevice/
PremarketSubmissions/ucm577696.htm.
If you need assistance, please contact
the Division of Industry and Consumer
Education at 800–638–2041 or 301–796–
7100 or email at DICE@fda.hhs.gov.
B. Foreign Businesses
If you are a foreign business, and wish
to qualify as a small business for FY
2024, submit the following:
1. A completed MDUFA Foreign
Small Business Certification Request for
a Business Headquartered Outside the
United States (Form FDA 3602A). Form
FDA 3602A is provided in the FDA
Forms database: https://www.fda.gov/
media/128059/download.
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
48875
2. A National Taxing Authority
Certification, completed by, and bearing
the official seal of, the National Taxing
Authority, if extant, of the country in
which the firm is headquartered. This
certification must show the amount of
gross receipts or sales for the most
recent tax year, in both U.S. dollars and
the local currency of the country, the
exchange rate used in converting the
local currency to U.S. dollars, and the
dates of the gross receipts or sales
collected.
If your firm is headquartered in a
country without a National Taxing
Authority, please contact the Division of
Industry and Consumer Education at
800–638–2041 or 301–796–7100 or
email at DICE@fda.hhs.gov.
3. For each of your affiliates, either:
• If the affiliate is a domestic (U.S.)
business, a signed copy of the affiliate’s
Federal (U.S.) Income Tax Return for the
most recent tax year (2022 or later), or
• If the affiliate is a foreign business
and cannot submit a Federal (U.S.)
Income Tax Return, a National Taxing
Authority Certification completed by,
and bearing the official seal of, the
National Taxing Authority, if extant, of
the country in which the firm is
headquartered. The National Taxing
Authority is the foreign equivalent of
the U.S. Internal Revenue Service. This
certification must show the amount of
gross receipts or sales for the most
recent tax year, in both U.S. dollars and
the local currency of the country, the
exchange rate used in converting the
local currency to U.S. dollars, and the
dates for the gross receipts or sales
collected. The business must also
submit a statement signed by the head
of the business’s firm or by its chief
financial officer that the applicant has
submitted certifications for all of its
affiliates, identifying the name of each
affiliate, or that the business has no
affiliates.
• If your affiliate is headquartered in
a country without a National Taxing
Authority, please contact the Division of
Industry and Consumer Education at
800–638–2041 or 301–796–7100 or
email at DICE@fda.hhs.gov.
4. Once you have completed your
Form FDA 3602A, print and sign the
form. Mail the completed form and your
supporting documentation, including
the following, to CDRH’s Medical
Device User Fee Small Business
Certification Request address, which is
available at the following website:
https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
HowtoMarketYourDevice/
PremarketSubmissions/ucm577696.htm.
E:\FR\FM\28JYN1.SGM
28JYN1
48876
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
• A copy of the most recent Federal
(U.S.) income tax return for each of your
affiliates headquartered in the U.S. and
• A copy of an MDUFA Foreign Small
Business Certification Request for each
of your foreign affiliates.
If you need assistance, please contact
the Division of Industry and Consumer
Education at 800–638–2041 or 301–796–
7100 or email at DICE@fda.hhs.gov.
lotter on DSK11XQN23PROD with NOTICES1
VI. Procedures for Paying Application
Fees
If your application or submission is
subject to a fee and your payment is
received by FDA between October 1,
2023, and September 30, 2024, you must
pay the fee in effect for FY 2024. To
avoid delay in the review of your
application, you should pay the
application fee at the time you submit
your application to FDA. The later of
the date that the application is received
in the reviewing center’s document
room or the date the U.S. Treasury
recognizes the payment determines
whether the fee rates for FY 2023 or FY
2024 apply. FDA must receive the
correct fee at the time that an
application is submitted, or the
application will not be accepted for
filing or review.
FDA requests that you follow the
steps below before submitting a medical
device application subject to a fee to
ensure that FDA links the fee with the
correct application. (Note: Do not send
your user fee check to FDA with the
application.)
A. Secure a Payment Identification
Number (PIN) and Medical Device User
Fee Cover Sheet From FDA Before
Submitting Either the Application or the
Payment
Log into the User Fee System at:
https://userfees.fda.gov/OA_HTML/
mdufmaCAcdLogin.jsp. Complete the
Medical Device User Fee cover sheet. Be
sure you choose the correct application
submission date range. (Two choices
will be offered until October 1, 2023.
One choice is for applications and fees
that will be received on or before
September 30, 2023, which are subject
to FY 2023 fee rates. A second choice
is for applications and fees received on
or after October 1, 2024, which are
subject to FY 2024 fee rates.) After
completing data entry, print a copy of
the Medical Device User Fee cover sheet
and note the unique PIN located in the
upper right-hand corner of the printed
cover sheet.
B. Electronically Transmit a Copy of the
Printed Cover Sheet With the PIN
When you are satisfied that the data
on the cover sheet is accurate,
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
electronically transmit that data to FDA
according to instructions on the screen.
Applicants are required to set up a user
account and password to assure data
security in the creation and electronic
submission of cover sheets.
C. Submit Payment for the Completed
Medical Device User Fee Cover Sheet
1. The preferred payment method is
online using electronic check
(Automated Clearing House (ACH) also
known as eCheck) or credit card
(Discover, VISA, MasterCard, American
Express). FDA has partnered with the
U.S. Department of the Treasury to
utilize Pay.gov, a web-based payment
system, for online electronic payment.
You may make a payment via electronic
check or credit card after submitting
your cover sheet. Secure electronic
payments can be submitted using the
User Fees Payment Portal at https://
userfees.fda.gov/pay. Note: Only full
payments are accepted. No partial
payments can be made online. Once you
search for your invoice, select ‘‘Pay
Now’’ to be redirected to Pay.gov.
Electronic payment options are based on
the balance due. Payment by credit card
is available for balances that are less
than $25,000. If the balance exceeds this
amount, only the ACH option is
available. Payments must be made using
U.S. bank accounts as well as U.S. credit
cards.
2. If paying with a paper check:
• All paper checks must be in U.S.
currency from a U.S. bank and made
payable to the Food and Drug
Administration. If needed, FDA’s tax
identification number is 53–0196965.
• Please write your application’s
unique PIN (from the upper right-hand
corner of your completed Medical
Device User Fee cover sheet) on your
check.
• Mail the paper check and a copy of
the completed cover sheet to: Food and
Drug Administration, P.O. Box 979033,
St. Louis, MO 63197–9000. (Please note
that this address is for payments of
application and annual report fees only
and is not to be used for payment of
annual establishment registration fees.)
If you prefer to send a check by a
courier, the courier may deliver the
check to: U.S. Bank, Attn: Government
Lockbox 979033, 1005 Convention
Plaza, St. Louis, MO 63101. (Note: This
U.S. Bank address is for courier delivery
only. If you have any questions
concerning courier delivery contact U.S.
Bank at 314–418–4013. This telephone
number is only for questions about
courier delivery.)
3. If paying with a wire transfer:
• Please include your application’s
unique PIN (from the upper right-hand
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
corner of your completed Medical
Device User Fee cover sheet) in your
wire transfer. Without the PIN, your
payment may not be applied to your
cover sheet and review of your
application may be delayed.
• The originating financial institution
may charge a wire transfer fee. If the
financial institution charges a wire
transfer fee it is required that you add
that amount to the payment to ensure
that the invoice is paid in full.
Use the following account
information when sending a wire
transfer: U.S. Department of the
Treasury, TREAS NYC, 33 Liberty St.,
New York, NY 10045, Acct. No.
75060099, Routing No. 021030004,
SWIFT: FRNYUS33.
FDA records the official application
receipt date as the later of the following:
(1) the date the application was received
by the FDA Document Control Center
for the reviewing Center or (2) the date
the U.S. Treasury recognizes the
payment.
D. Submit Your Application to FDA
With a Copy of the Completed Medical
Device User Fee Cover Sheet
Please submit your application and a
copy of the completed Medical Device
User Fee cover sheet to the address
located at https://www.fda.gov/
cdrhsubmissionaddress.
VII. Procedures for Paying the Annual
Fee for Periodic Reporting
You will be invoiced at the end of the
quarter in which your PMA Periodic
Report is due. Invoices will be sent
based on the details included on your
PMA file. You are responsible for
ensuring FDA has your current billing
information, and you may update your
contact information for the PMA by
submitting an amendment to the
pending PMA or a supplement to the
approved PMA.
1. The preferred payment method is
online using electronic check (ACH also
known as eCheck) or credit card
(Discover, VISA, MasterCard, American
Express). Secure electronic payments
can be submitted using the User Fees
Payment Portal at https://
userfees.fda.gov/pay (Note: Only full
payments are accepted. No partial
payments can be made online). Once
you search for your invoice, select ‘‘Pay
Now’’ to be redirected to Pay.gov. Note
that electronic payment options are
based on the balance due. Payment by
credit card is available for balances that
are less than $25,000. If the balance
exceeds this amount, only the ACH
option is available. Payments must be
made using U.S. bank accounts as well
as U.S. credit cards.
E:\FR\FM\28JYN1.SGM
28JYN1
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
lotter on DSK11XQN23PROD with NOTICES1
2. If paying with a paper check: The
check must be in U.S. currency from a
U.S. bank and made payable to the Food
and Drug Administration. If needed,
FDA’s tax identification number is 53–
0196965.
• Please write your invoice number
on the check.
• Mail the paper check and a copy of
the invoice to: Food and Drug
Administration, P.O. Box 979033, St.
Louis, MO 63197–9000. (Please note
that this address is for payments of
application and annual report fees only
and is not to be used for payment of
annual establishment registration fees.)
To send a check by a courier, the
courier must deliver the check and
printed copy of the cover sheet to U.S.
Bank, Attn: Government Lockbox
979033, 1005 Convention Plaza, St.
Louis, MO 63101. (Note: This U.S. Bank
address is for courier delivery only. If
you have any questions concerning
courier delivery, contact U.S. Bank at
314–418–4013. This telephone number
is only for questions about courier
delivery.)
3. When paying by a wire transfer, it
is required that the invoice number is
included; without the invoice number
the payment may not be applied. If the
payment amount is not applied, the
invoice amount would be referred to
collections. The originating financial
institution may charge a wire transfer
fee. If the financial institution charges a
wire transfer fee, it is required that you
add that amount to the payment to
ensure that the invoice is paid in full.
Use the following account
information when sending a wire
transfer: U.S. Department of the
Treasury, TREAS NYC, 33 Liberty St.,
New York, NY 10045, Acct. No.
75060099, Routing No. 021030004,
SWIFT: FRNYUS33.
VIII. Procedures for Paying Annual
Establishment Registration Fees
To pay the annual establishment
registration fee, firms must access the
Device Facility User Fee (DFUF) website
at https://userfees.fda.gov/OA_HTML/
furls.jsp. (FDA has verified the website
address, but FDA is not responsible for
any subsequent changes to the website
address after this document publishes in
the Federal Register.) Create a DFUF
order and you will be issued a PIN
when you place your order. After
payment has been processed, you will
be issued a payment confirmation
number (PCN). You will not be able to
register your establishment if you do not
have a PIN and a PCN. An establishment
required to pay an annual establishment
registration fee is not legally registered
in FY 2024 until it has completed the
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
steps below to register and pay any
applicable fee (see 21 U.S.C. 379j(f)(2)).
Companies that do not manufacture
any product other than a licensed
biologic are required to register in the
Blood Establishment Registration (BER)
system. FDA’s Center for Biologics
Evaluation and Research (CBER) will
send establishment registration fee
invoices annually to these companies.
A. Submit a DFUF Order With a PIN
From FDA Before Registering or
Submitting Payment
To submit a DFUF Order, you must
create or have previously created a user
account and password for the user fee
website listed previously in this section.
After creating a username and
password, log into the Establishment
Registration User Fee FY 2024 store.
Complete the DFUF order by entering
the number of establishments you are
registering that require payment. When
you are satisfied that the information in
the order is accurate, electronically
transmit that data to FDA according to
instructions on the screen. Print a copy
of the final DFUF order and note the
unique PIN located in the upper righthand corner of the printed order.
B. Pay for Your DFUF Order
Unless paying by U.S. credit card, all
payments must be in U.S. currency and
drawn on a U.S. bank.
1. If paying by credit card or
electronic check (ACH or eCheck): The
DFUF order will include payment
information, including details on how
you can pay online using a credit card
or electronic check. Follow the
instructions provided to make an
electronic payment.
2. If paying with a paper check: The
check must be in U.S. currency and
drawn on a U.S. bank, and mailed to:
Food and Drug Administration, P.O.
Box 979108, St. Louis, MO 63197–9000.
(Note: This address is different from the
address for payments of application and
annual report fees and is to be used only
for payment of annual establishment
registration fees.)
If a check is sent by a courier that
requests a street address, the courier can
deliver the check to: U.S. Bank, Attn:
Government Lockbox 979108, 1005
Convention Plaza, St. Louis, MO 63101.
(Note: This U.S. Bank address is for
courier delivery only. If you have any
questions concerning courier delivery,
contact U.S. Bank at 314–418–4013.
This telephone number is only for
questions about courier delivery.)
Please make sure that both of the
following are written on your check: (1)
the FDA post office box number (P.O.
Box 979108) and (2) the PIN that is
PO 00000
Frm 00092
Fmt 4703
Sfmt 4703
48877
printed on your order. Include a copy of
your printed order when you mail your
check.
3. If paying with a wire transfer: Wire
transfers may also be used to pay annual
establishment registration fees. To send
a wire transfer, please read and comply
with the following information:
Include your order’s unique PIN (in
the upper right-hand corner of your
completed DFUF order) in your wire
transfer. Without the PIN, your payment
may not be applied to your facility and
your registration may be delayed.
The originating financial institution
may charge a wire transfer fee. If the
financial institution charges a wire
transfer fee, it is required that you add
that amount to the payment to ensure
that the invoice is paid in full. Use the
following account information when
sending a wire transfer: U.S. Dept. of the
Treasury, TREAS NYC, 33 Liberty St.,
New York, NY 10045, Acct. No.
75060099, Routing No. 021030004,
SWIFT: FRNYUS33. If needed, FDA’s
tax identification number is 53–
0196965.
C. Complete the Information Online To
Update Your Establishment’s Annual
Registration for FY 2024, or To Register
a New Establishment for FY 2024
Go to the Center for Devices and
Radiological Health’s website at https://
www.fda.gov/medical-devices/howstudy-and-market-your-device/deviceregistration-and-listing and click the
‘‘Access Electronic Registration’’ link on
the left side of the page. This opens a
new page with important information
about the FDA Unified Registration and
Listing System (FURLS). After reading
this information, click on the ‘‘Access
Electronic Registration’’ link in the
middle of the page. This link takes you
to an FDA Industry Systems page with
tutorials that demonstrate how to create
a new FURLS user account if your
establishment did not create an account
in FY 2023. Manufacturers of licensed
biologics should register in the
electronic Blood Establishment
Registration (eBER) system at https://
www.fda.gov/vaccines-blood-biologics/
guidance-compliance-regulatoryinformation-biologics/biologicsestablishment-registration.
Enter your existing account ID and
password to log into FURLS. From the
FURLS/FDA Industry Systems menu,
click on the Device Registration and
Listing Module (DRLM) of FURLS
button. New establishments will need to
register, and existing establishments
will update their annual registration
using choices on the DRLM menu.
When you choose to register or update
your annual registration, the system will
E:\FR\FM\28JYN1.SGM
28JYN1
48878
Federal Register / Vol. 88, No. 144 / Friday, July 28, 2023 / Notices
prompt you through the entry of
information about your establishment
and your devices. If you have any
problems with this process, email:
reglist@cdrh.fda.gov or call 301–796–
7400 for assistance. (Note: This email
address and this telephone number are
for assistance with establishment
registration only; they are not to be used
for questions related to other aspects of
medical device user fees.) Problems
with the eBER system should be
directed to https://
www.accessdata.fda.gov/scripts/email/
cber/bldregcontact.cfm or call 240–402–
8360.
D. Enter Your DFUF Order PIN and PCN
After completing your annual or
initial registration and device listing,
you will be prompted to enter your
DFUF order PIN and PCN, when
applicable. This process does not apply
to establishments engaged only in the
manufacture, preparation, propagation,
compounding, or processing of licensed
biologic devices. CBER will send
invoices for payment of the
establishment registration fee to such
establishments.
IX. Small Business Fee Reductions and
Fee Waivers
lotter on DSK11XQN23PROD with NOTICES1
To qualify for reduced fees for small
businesses or a small business fee
waiver, please see the requirements for
qualification provided in Section V.
How To Qualify as a Small Business for
Purposes of Medical Device Fees. The
applicant should submit a Small
Business Certification Request and the
supporting materials showing you
qualify as a small business at least 60
days before you send your submission
to FDA. FDA will review your
information and determine whether you
qualify as a small business eligible for
the reduced fee and/or fee waiver. If you
make a submission before FDA finds
that you qualify as a small business, you
must pay the standard (full) fee for that
submission.
If you need assistance, please contact
the Division of Industry and Consumer
Education at 800–638–2041 or 301–796–
7100 or email at DICE@fda.hhs.gov.
A. Premarket Approval Fee Reduction
or Waiver
A small business applicant may
request to pay a reduced rate for
premarket approval fees. An applicant
may also request a fee waiver for their
first premarket application or premarket
report (see 21 U.S.C. 379j(d)).
VerDate Sep<11>2014
17:16 Jul 27, 2023
Jkt 259001
B. Premarket Notification Submission
Fee Reduction
A small business applicant may
request to pay a reduced rate for a
premarket notification submission.
C. Annual Establishment Registration
Fee
There is no small business waiver for
the annual establishment registration
fee; all establishments pay the same fee.
X. Refunds
To qualify for consideration for a
refund, a person shall submit to FDA a
written request for a refund not later
than 180 days after such fee is due. FDA
has discretion to refund a fee or a
portion of the fee. A determination by
FDA concerning a refund shall not be
reviewable. For more information on
qualifying and submitting a refund, see
21 U.S.C. 379j(a)(2)(D).
Dated: July 21, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–15919 Filed 7–27–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–2895]
Outsourcing Facility Fee Rates for
Fiscal Year 2024
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
fiscal year (FY) 2024 rates for the
establishment and reinspection fees
related to entities that compound
human drugs and elect to register as
outsourcing facilities under the Federal
Food, Drug, and Cosmetic Act (FD&C
Act). The FD&C Act authorizes FDA to
assess and collect an annual
establishment fee from outsourcing
facilities, as well as a reinspection fee
for each reinspection of an outsourcing
facility. This document establishes the
FY 2024 rates for the small business
establishment fee ($6,196), the nonsmall business establishment fee
($20,036), and the reinspection fee
($18,588) for outsourcing facilities;
provides information on how the fees
for FY 2024 were determined; and
describes the payment procedures
outsourcing facilities should follow.
SUMMARY:
PO 00000
Frm 00093
Fmt 4703
Sfmt 4703
These fee rates are effective
October 1, 2023, and will remain in
effect through September 30, 2024.
ADDRESSES: Office of Financial
Management, Food and Drug
Administration, 4041 Powder Mill Rd.,
Rm. 61075, Beltsville, MD 20705–4304.
FOR FURTHER INFORMATION CONTACT: For
more information on human drug
compounding and outsourcing facility
fees, visit FDA’s website at: https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
human-drug-compounding.
For questions relating to this notice:
Olufunmilayo Ariyo, Office of Financial
Management, Food and Drug
Administration, 4041 Powder Mill Rd.,
Beltsville, MD 20705–4304, 240–402–
4989; or the User Fee Support Staff at
OO-OFBAP-OFM-UFFS-Government@
fda.hhs.gov.
DATES:
SUPPLEMENTARY INFORMATION:
I. Background
Under section 503B of the FD&C Act
(21 U.S.C. 353b), a human drug
compounder can register with FDA as
an ‘‘outsourcing facility.’’ Outsourcing
facilities, as defined in section
503B(d)(4), are facilities that meet all
the conditions described in section
503B(a), including registering with FDA
as an outsourcing facility and paying an
annual establishment fee. If the
conditions of section 503B are met, a
drug compounded by or under the
direct supervision of a licensed
pharmacist in an outsourcing facility is
exempt from three sections of the FD&C
Act: (1) section 502(f)(1) (21 U.S.C.
352(f)(1)), concerning the labeling of
drugs with adequate directions for use;
(2) section 505 (21 U.S.C. 355),
concerning the approval of human drug
products under new drug applications
or abbreviated new drug applications;
and (3) section 582 (21 U.S.C. 360eee–
1), concerning drug supply chain
security requirements. Drugs
compounded in outsourcing facilities
are not exempt from the requirements of
section 501(a)(2)(B) of the FD&C Act (21
U.S.C. 351(a)(2)(B)), concerning current
good manufacturing practice
requirements for drugs.
Section 744K of the FD&C Act (21
U.S.C. 379j–62) authorizes FDA to
assess and collect the following fees
associated with outsourcing facilities:
(1) an annual establishment fee from
each outsourcing facility and (2) a
reinspection fee from each outsourcing
facility subject to a reinspection (see
section 744K(a)(1) of the FD&C Act).
Under statutorily defined conditions, a
qualified applicant may pay a reduced
E:\FR\FM\28JYN1.SGM
28JYN1
Agencies
[Federal Register Volume 88, Number 144 (Friday, July 28, 2023)]
[Notices]
[Pages 48870-48878]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-15919]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-N-2965]
Medical Device User Fee Rates for Fiscal Year 2024
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the fee
rates and payment procedures for medical device user fees for fiscal
year (FY) 2024. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as
amended by the Medical Device User Fee Amendments of 2022 (MDUFA V),
authorizes FDA to collect user fees for certain medical device
submissions and annual fees both for certain periodic reports and for
establishments subject to registration. This notice establishes the fee
rates for FY 2024, which apply from October 1, 2023, through September
30, 2024, and provides information on how the fees for FY 2024 were
determined, the payment procedures you should follow, and how you may
qualify for reduced small business fees.
FOR FURTHER INFORMATION CONTACT:
For information on Medical Device User Fees: https://www.fda.gov/industry/fda-user-fee-programs/medical-device-user-fee-amendments-mdufa.
For questions relating to the MDUFA Small Business Program, please
visit the Center for Devices and Radiological Health's website: https://www.fda.gov/medical-devices/premarket-submissions/reduced-medical-device-user-fees-small-business-determination-sbd-program.
For questions relating to this notice: Olufunmilayo Ariyo, Office
of Financial Management, Food and Drug Administration, 4041 Powder Mill
Rd., Beltsville, MD 20705-4304, 240-402-4989; or the User Fee Support
Staff at [email protected].
SUPPLEMENTARY INFORMATION:
I. Background
The FD&C Act, as amended by MDUFA V, authorizes FDA to collect user
fees for certain medical device submissions and annual fees both for
certain periodic reports and for establishments subject to
registration. Section 738 of the FD&C Act (21 U.S.C. 379j) establishes
fees for certain medical device applications, submissions, supplements,
notices, and requests (for
[[Page 48871]]
simplicity, this document refers to these collectively as
``submissions'' or ``applications''); for periodic reporting on class
III devices; and for the registration of certain establishments.
Under the FD&C Act, the fee rate for each type of submission is set
at a specified percentage of the standard fee for a premarket
application (a premarket application is a premarket approval
application (PMA), a product development protocol (PDP), or a biologics
license application (BLA)). The FD&C Act specifies the base fee for a
premarket application for each year from FY 2023 through FY 2027; the
base fee for a premarket application received by FDA during FY 2024 is
$435,000. From this starting point, this document establishes FY 2024
fee rates for certain types of submissions, and for periodic reporting,
by applying criteria specified in the FD&C Act. Under statutorily
defined conditions, a qualified applicant may receive a fee waiver or
may pay a lower small business fee (see 21 U.S.C. 379j(d) and (e)). For
more information on fee waivers, please see Section IX. Small Business
Fee Reductions and Fee Waivers.
The FD&C Act specifies the base fee for establishment registration
for each year from FY 2023 through FY 2027; the base fee for an
establishment registration in FY 2024 is $6,875. Each establishment
that is registered (or is required to register) with the Secretary of
Health and Human Services under section 510 of the FD&C Act (21 U.S.C.
360) because such establishment is engaged in the manufacture,
preparation, propagation, compounding, or processing of a device is
required to pay the annual fee for establishment registration.
II. Total Revenue Amount for FY 2024
The total revenue amount for FY 2024 is $335,750,000, as set forth
in the statute prior to the inflation adjustment (see 21 U.S.C.
379j(b)(3)). MDUFA V directs FDA to use the yearly total revenue amount
as a starting point to set the standard fee rates for each fee type.
The fee calculations for FY 2024 are described in this document.
Inflation Adjustment
MDUFA specifies that the $335,750,000 is to be adjusted for
inflation increases for FY 2024 using two separate adjustments: one for
payroll costs and one for non-payroll costs (see 21 U.S.C. 379j(c)(2)).
The base inflation adjustment for FY 2024 is the sum of one plus the
two separate adjustments and is compounded as specified in the statute
(see 21 U.S.C. 379j(c)(2)(C) and 379j(c)(2)(B)).
The component of the inflation adjustment for payroll costs is the
average annual percent change in the cost of all personnel compensation
and benefits (PC&B) paid per full-time equivalent position (FTE) at FDA
for the first 3 of the 4 preceding FYs, multiplied by 0.60, or 60
percent (see 21 U.S.C. 379j(c)(2)(C)).
Table 1 summarizes the actual cost and FTE data for the specified
FYs, provides the percent change from the previous fiscal year, and
provides the average percent change over the first 3 of the 4 fiscal
years preceding FY 2024. The 3-year average is 3.9280 percent
(rounded).
Table 1--FDA PC&Bs Each Year and Percent Change
----------------------------------------------------------------------------------------------------------------
FY 2020 FY 2021 FY 2022 3-Year average
----------------------------------------------------------------------------------------------------------------
Total PC&B.............................. $2,875,592,000 $3,039,513,000 $3,165,477,000 ................
Total FTE............................... $17,535 $18,501 $18,474 ................
PC&B per FTE............................ $163,922 $164,289 $171,348 ................
Percent change from previous year....... 7.3063% 0.1811% 4.2967% 3.9280%
----------------------------------------------------------------------------------------------------------------
The payroll adjustment is 3.9280 percent multiplied by 60 percent,
or 2.3568 percent. The statute specifies that the component of the
inflation adjustment for non-payroll costs for FY 2024 is the average
annual percent change that occurred in the Consumer Price Index (CPI)
for urban consumers (Washington-Arlington-Alexandria, DC-VA-MD-WV; Not
Seasonally Adjusted; All Items; Annual Index) for the first 3 of the
preceding 4 years of available data multiplied by 0.40, or 40 percent
(see 21 U.S.C. 379j(c)(2)(C)).
Table 2 provides the summary data and the 3-year average percent
change in the specified CPI for the Washington-Arlington-Alexandria
area. These data are published by the Bureau of Labor Statistics and
can be found on their website under series Id CUURS35ASA0 at: https://data.bls.gov/pdq/SurveyOutputServlet?data_tool=dropmap&series_id=CUURS35ASA0,CUUSS35ASA0.
Table 2--Annual and 3-Year Average Percent Change in Washington-Arlington-Alexandria Area CPI
----------------------------------------------------------------------------------------------------------------
2020 2021 2022 3-Year average
----------------------------------------------------------------------------------------------------------------
Annual CPI.............................. 267.157 277.728 296.117 ................
Annual Percent Change................... 0.8989% 3.9568% 6.6212% ................
3-Year Average Percent Change in CPI.... ................ ................ ................ 3.8256%
----------------------------------------------------------------------------------------------------------------
The non-payroll adjustment is 3.8256 percent multiplied by 40
percent, or 1.5302 percent. Next, the payroll adjustment (2.3568
percent or 0.023568) is added to the non-payroll adjustment (1.5302
percent or .015302), for a total of 3.8870 percent (or 0.038870). To
complete the inflation adjustment, 1 (100 percent or 1.0) is added for
a total base inflation adjustment of 1.03887 for FY 2024.
MDUFA V provides for this inflation adjustment to be compounded for
FY 2023 and each subsequent fiscal year (see 21 U.S.C.
379j(c)(2)(B)(ii)). To complete the compounded inflation adjustment for
FY 2024, the FY 2023 compounded adjustment (1.038870) is multiplied by
the FY 2024 base inflation adjustment (1.038935) to reach the
applicable inflation adjustment of 1.079318 (rounded) for FY 2024. We
then multiply the total revenue amount for FY 2024 ($335,750,000) by
1.079318, yielding an inflation adjusted total revenue amount of
$362,381,000 (rounded to the nearest thousand dollars).
[[Page 48872]]
III. Adjustments to Base Fee Amounts for FY 2024
Under the FD&C Act, all submission fees and the periodic reporting
fee are set as a percent of the standard (full) fee for a premarket
application (see 21 U.S.C. 379j(a)(2)(A)).
A. Inflation Adjustment
MDUFA specifies that the base fees of $435,000 (premarket
application) and $6,875 (establishment registration) are to be adjusted
for FY 2024 using the same methodology as that for the total revenue
inflation adjustment in section II (see 21 U.S.C. 379j(c)(2)(D)(i)).
Multiplying the base fees by the compounded inflation adjustment of
1.079318 yields inflation adjusted base fees of $469,503 (premarket
application) and $7,420 (establishment registration).
B. Further Adjustments To Generate the Inflation-Adjusted Total Revenue
Amount
After the applicable inflation adjustment to fees is done, FDA may
increase, if necessary to achieve the inflation adjusted total revenue
amount, the base fee amounts on a uniform proportionate basis (see 21
U.S.C. 379j(c)(2)(D)(ii)). After this adjustment, if necessary, FDA may
further increase the base establishment registration fees to generate
the inflation-adjusted total revenue amount (see 21 U.S.C. 379j(c)(3)).
C. MDUFA V Adjustments Solely to Registration Fees
MDUFA V has three new potential adjustments that will not change
the total revenue amount but may impact collections by increasing or
decreasing establishment registration base fees only. These adjustments
are the performance improvement adjustment, the hiring adjustment, and
the operating reserve adjustment. Only the operating reserve adjustment
is potentially applicable in FY 2024.
1. Performance Improvement Adjustment
For FY 2024, there is no performance improvement adjustment.
Beginning with FY 2025, this adjustment allows FDA to collect fees in
addition to the total revenue amount in FYs 2025, 2026, and 2027, if
the Agency meets certain performance goals in FYs 2023, 2024, and 2025.
If applicable, this provision further increases base establishment
registration fee amounts to achieve an increase in total fee
collections equal to the applicable performance improvement adjustment,
which is set forth in the statute (see 21 U.S.C. 379j(c)(4)).
2. Hiring Adjustment
For FY 2024, there is no hiring adjustment. Beginning with FY 2025,
this adjustment provides for the reduction of base establishment
registration fees in FYs 2025, 2026, and 2027, if specified hiring
goals for FYs 2023, 2024, and 2025 are not met by a certain threshold.
The hiring adjustment would serve to decrease the base establishment
registration fee amounts as necessary to achieve a reduction in total
fee collections equal to the hiring adjustment amount, which is set
forth in the statute (see 21 U.S.C. 379j(c)(5)).
3. Operating Reserve Adjustment
For FYs 2023 to 2027, the operating reserve adjustment requires FDA
to decrease base establishment registration fees if the amount of
operating reserves of carryover user fees exceeds the ``designated
amount'' and such reduction is necessary to provide for not more than
such designated amount of operating reserves of carryover user fees
(see 21 U.S.C. 379j(c)(6)). In making this calculation for FYs 2023 to
2026, a certain amount is excluded from the designated amount and is
not subject to the decrease (see 21 U.S.C. 379j(c)(6)(C)). For FY 2024,
this excluded amount is $100,600,981.
The designated amount is equal to the sum of 13 weeks of operating
reserves of carryover user fees plus 1 month of operating reserves
described in 21 U.S.C. 379j(c)(8) (see 21 U.S.C. 379j(c)(6)(B)).
To determine the 13-week operating reserves of carryover user fees
amount, the FY 2024 inflation-adjusted total revenue amount,
$362,381,000 is divided by 52, and then multiplied by 13. The 13-week
operating reserve amount for FY 2024 is $90,595,250.
To determine the 1 month of operating reserves described in 21
U.S.C. 379j(c)(8), the FY 2024 inflation-adjusted total revenue amount
of $362,381,000 is divided by 12. The 1 month of operating reserves for
FY 2024 is $30,198,417.
For FY 2024, the designated amount is equal to the 13-week
operating reserve of $90,595,250 plus the 1 month of operating reserves
of $30,198,417, totaling $120,793,667.
To determine the FY 2023 end-of-year operating reserves of
carryover user fees amount, FDA combined the actual collections and
obligations at the end of the third quarter (June 2023) and added the
forecasted collections and obligations for the fourth quarter of FY
2023 to generate a full year estimate for FY 2023. The estimated end-
of-year FY 2023 operating reserves of carryover user fees is
$30,019,132. (Note, this amount includes the 1-month reserve.)
Note that under MDUFA V, for the purposes of calculating the
operating reserve adjustment, this amount does not include user fee
funds considered unappropriated ($26,680,243) or unearned revenue
($65,418,275). In addition, as noted above, for purposes of the
operating reserve adjustment, operating reserves of carryover user fees
do not include the estimated $100,600,981 remaining to spend at the end
of FY 2023 from the total of $118,000,000 intended to support the Total
Product Life Cycle Advisory Program Pilot and Third-Party Review
programs.
Because the estimated end-of-year FY 2023 MDUFA operating reserves
of carryover user fees amount totaling $30,019,132 does not exceed the
FY 2024 designated amount of $120,793,667 FDA will not decrease the
base establishment registration fee amounts for FY 2024 to provide for
not more than such designated amount.
IV. Calculation of Fee Rates
As noted in section II, the total revenue amount after the
applicable inflation adjustment is $362,381,000 (rounded to the nearest
thousand dollar). As noted in section III, there is no MDUFA V
adjustment solely to registration fees for FY 2024.
Table 3A provides fee-paying submission counts excluding
establishment registration for the last 3 years and the 3-year average.
Table 3B provides establishment registration fee-paying submission
counts for the last 5 years and the 5-year average. Historically, FDA
has estimated the total number of fee-paying submission counts it
expects to receive during the next fiscal year by averaging the number
of fee-paying submission counts received in the 3 most recently
completed fiscal years; for FY 2024 fee-setting, this would be an
average of FY 2020 through FY 2022. FDA received an abnormally high
volume of fee paying establishment registrations due to the COVID-19
pandemic in FY 2020 and FY 2021. The surge in fee-paying establishment
registrations has been declining starting in FY 2022, trending back
toward pre-pandemic levels. In an effort to normalize the projected
volume of establishment registration submissions for the FY 2024 fee-
setting calculation and more accurately project the associated
establishment registration revenue, FDA decided to average the number
of establishment registrations from FY 2018 through FY 2022. FDA
believes a 5-year average to estimate establishment registration volume
will
[[Page 48873]]
minimize the impact of the surge in fee paying establishment
registration volume in FY 2020 and FY 2021.
Table 3A--Three-Year Average of Fee-Paying Submissions (Excluding Establishment Registration)
----------------------------------------------------------------------------------------------------------------
Application type FY 2020 actual FY 2021 actual FY 2022 actual 3-Year average
----------------------------------------------------------------------------------------------------------------
Full Fee applications......................... 29 25 18 24
Small Business............................ 7 5 3 5
Panel-Track Supplements....................... 23 31 21 25
Small Business............................ 6 6 1 4
De Novo Classifications....................... 20 16 23 20
Small Business............................ 47 42 53 47
180-Day Supplements........................... 124 98 93 105
Small Business............................ 20 34 31 28
Real-Time Supplements......................... 175 150 140 155
Small Business............................ 28 20 12 20
510(k)s....................................... 2,048 2,133 2,012 2,064
Small Business............................ 1,667 1,846 1,757 1,757
30-Day Notice (Note also includes counts for 870 843 782 832
135 Day Supplements).........................
Small Business............................ 104 77 67 83
513(g)(21 U.S.C. 360c(g)) Request for 96 83 93 91
Classification Information...................
Small Business............................ 57 53 58 56
Annual Fee for Periodic Reporting............. 622 613 620 618
Small Business............................ 95 84 87 89
----------------------------------------------------------------------------------------------------------------
Table 3B--Five-Year Average of Fee-Paying Establishment Registration Submissions
----------------------------------------------------------------------------------------------------------------
Application type FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 5-Year average
----------------------------------------------------------------------------------------------------------------
Establishment Registrations. 27,544 27,728 41,942 33,812 31,748 32,555
----------------------------------------------------------------------------------------------------------------
The information in tables 3A and 3B is necessary to estimate the
amount of revenue that will be collected based on the fee amounts.
Tables 4A and B display the FY 2024 base fees set in statute (column
one) and the inflation adjusted base fees (per calculations in section
III.A.) (column two). Using the inflation adjusted fees, the 3-year
average of fee-paying submissions (excluding establishment
registration), and the 5-year average of fee-paying establishment
registration submissions, collections are projected to total
$351,531,781 which is $10,849,219 lower than the inflation adjusted
total revenue amount (in section II). Accordingly, the next step in the
fee setting process is to increase the base fee amounts on a uniform
proportionate basis to generate the inflation adjusted total revenue
amounts (see 21 U.S.C. 379j(c)(2)(D)(ii) and table 4A, column three).
Applying these further adjusted fee rates to the 3-year average of
fee paying submissions, and the 5-year average of fee-paying
establishment registration submissions results in estimated total fee
collections of $362,040,886, which is still $340,114 lower than the
inflation adjusted total revenue amount (in Section II). The next step
in the fee setting process, after the adjustment in (2)(D) is done, is
to increase the base establishment registration fee amount as necessary
for total fee collections to generate the inflation adjusted total
revenue amount, as adjusted under paragraph (2) (see 21 U.S.C.
379j(c)(3)). Accordingly, the base establishment registration fee was
increased by $11 for an establishment registration fee rate of $7,653
(see 21 U.S.C. 379j(c)(3)). The fees in column three in tables 4A and
4B are those we are establishing for FY 2024, which are the standard
fees.
Table 4A--Fees Needed To Achieve New FY 2024 Revenue Target
----------------------------------------------------------------------------------------------------------------
FY 2024
inflation Adjusted FY 2024
FY 2024 adjusted fees to meet 3-Year average FY 2024
Application type statutory fees statutory base revenue target of fee-paying revenue from
(base fees) fees (standard (standard fees) submissions adjusted fees
fees)
----------------------------------------------------------------------------------------------------------------
Full Fee Applications....... $435,000 $469,503 $483,560 24 $11,605,440
Small Business.......... 108,750 117,376 120,890 5 604,450
Panel-Track Supplement...... 348,000 375,603 386,848 25 9,671,200
Small Business.......... 87,000 93,901 96,712 4 386,848
De Novo Classification 130,500 140,851 145,068 20 2,901,360
Request....................
Small Business.......... 32,625 35,213 36,267 47 1,704,549
180-Day Supplements......... 65,250 70,425 72,534 105 7,616,070
Small Business.......... 16,313 17,606 18,134 28 507,752
Real-Time Supplements....... 30,450 32,865 33,849 155 5,246,595
Small Business.......... 7,613 8,216 8,462 20 169,240
510(k)s..................... 19,575 21,128 21,760 2,064 44,912,640
Small Business.......... 4,894 5,282 5,440 1,757 9,558,080
30-Day Notice............... 6,960 7,512 7,737 832 6,437,184
[[Page 48874]]
Small Business.......... 3,480 3,756 3,869 83 321,127
513(g) Request for 5,873 6,338 6,528 91 594,048
Classification Information.
Small Business.......... 2,937 3,169 3,264 56 182,784
Annual Fee for Periodic 15,225 16,433 16,925 618 10,459,650
Reporting..................
Small Business.......... 3,806 4,108 4,231 89 376,559
-----------------------------------------------------------------------------------
Total............... .............. ................ ................ .............. 113,255,576
----------------------------------------------------------------------------------------------------------------
Table 4B--Fees Needed To Achieve New FY 2024 Revenue Target
--------------------------------------------------------------------------------------------------------------------------------------------------------
FY 2024 inflation
FY 2024 adjusted Adjusted FY 2024 5-Year average FY 2024 revenue
Application type statutory fees statutory base fees to meet of fee-paying from adjusted
(base fees) fees (standard revenue target submissions fees
fees) (standard fees)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Establishment Registrations.................................... $6,875 $7,420 $7,653 32,555 $249,143,415
--------------------------------------------------------------------------------------------------------------------------------------------------------
The standard fee (adjusted base amount) for a premarket
application, including a BLA, and for a premarket report and a BLA
efficacy supplement, is $483,560 for FY 2024. The fees set by reference
to the standard fee for a premarket application are:
For a panel-track supplement, 80 percent of the standard
fee;
For a de novo classification request, 30 percent of the
standard fee;
For a 180-day supplement, 15 percent of the standard fee;
For a real-time supplement, 7 percent of the standard fee;
For an annual fee for periodic reporting concerning a
class III device, 3.5 percent of the standard fee;
For a 510(k) premarket notification, 4.5 percent of the
standard fee;
For a 30-day notice, 1.6 percent of the standard fee; and
For a 513(g) request for classification information, 1.35
percent of the standard fee.
For all submissions other than a 30-day notice and a 513(g) request
for classification information, the small business fee is 25 percent of
the standard (full) fee for the submission (see 21 U.S.C. 379j(d)(2)(C)
and (e)(2)(C)). For a 30-day notice and a 513(g) request for
classification information, the small business fee is 50 percent of the
standard (full) fee for the submission (see 21 U.S.C. 379j(d)(2)(C)).
The annual fee for establishment registration, after adjustments,
is set at $7,653 for FY 2024. For FY 2024, there is no small business
waiver for the annual establishment registration fee; all
establishments pay the same fee.
For more information on reduced fees and waivers for small
businesses, please see Section IX. Small Business Fee Reductions and
Fee Waivers.
Table 5 summarizes the FY 2024 rates for all medical device fees.
Table 5--Medical Device Fees for FY 2024
----------------------------------------------------------------------------------------------------------------
Standard fee (as a percent of the
Application fee type standard fee for a premarket FY 2024 FY 2024 small
application) standard fee business fee
----------------------------------------------------------------------------------------------------------------
Premarket application (a PMA submitted Base fee specified in statute......... $483,560 $120,890
under section 515(c)(1) of the FD&C Act
(21 U.S.C. 360e(c)(1)), a PDP submitted
under section 515(f) of the FD&C Act,
or a BLA submitted under section 351 of
the Public Health Service Act (the PHS
Act) (42 U.S.C. 262)).
Premarket report (submitted under 100................................... 483,560 120,890
section 515(c)(2) of the FD&C Act).
Efficacy supplement (to an approved BLA 100................................... 483,560 120,890
under section 351 of the PHS Act).
Panel-track supplement.................. 80.................................... 386,848 96,712
De novo classification request.......... 30.................................... 145,068 36,267
180-day supplement...................... 15.................................... 72,534 18,134
Real-time supplement.................... 7..................................... 33,849 8,462
510(k) premarket notification submission 4.5................................... 21,760 5,440
30-day notice........................... 1.60.................................. 7,737 3,869
513(g) request for classification 1.35.................................. 6,528 3,264
information.
Annual Fee Type......................... ...................................... .............. ..............
Annual fee for periodic reporting on a 3.50.................................. 16,925 4,231
class III device.
Annual establishment registration fee Base fee specified in statute......... 7,653 7,653
(to be paid by the establishment
engaged in the manufacture,
preparation, propagation, compounding,
or processing of a device, as defined
by 21 U.S.C. 379i(14)).
----------------------------------------------------------------------------------------------------------------
[[Page 48875]]
V. How To Qualify as a Small Business for Purposes of Medical Device
Fees
If your business, including your affiliates, has gross receipts or
sales of no more than $100 million for the most recent tax year, you
may qualify for reduced small business fees. If your business,
including your affiliates, has gross sales or receipts of no more than
$30 million, you may also qualify for a waiver of the fee for your
first premarket application (i.e., PMA, PDP, or BLA) or premarket
report. If you want to pay the small business fee rate for a submission
or you want to receive a waiver of the fee for your first premarket
application or premarket report, you must submit the materials showing
you qualify as a small business at least 60 days before you send your
submission to FDA. For more information on fee waivers or reductions,
please see Section IX. Small Business Fee Reductions and Fee Waivers.
Please note that the establishment registration fee is not eligible
for a reduced small business fee. As a result, if the establishment
registration fee is the only medical device user fee that you will pay
in FY 2024, you should not submit a Small Business Certification
Request. FDA will review your information and determine whether you
qualify as a small business eligible for the reduced fee and/or fee
waiver. If you make a submission before FDA finds that you qualify as a
small business, you must pay the standard (full) fee for that
submission.
If your business qualified as a small business for FY 2023, your
status as a small business will expire at the close of business on
September 30, 2023. You must re-qualify for FY 2024 in order to pay
small business fees during FY 2024.
A. Domestic (U.S.) Businesses
If you are a domestic (U.S.) business and wish to qualify as a
small business for FY 2024, submit the following to FDA:
1. A completed MDUFA Small Business Certification Request for a
Business Headquartered in the United States (Form FDA 3602). Form FDA
3602 is provided in the FDA Forms database: https://www.fda.gov/media/128050/download.
2. A signed copy of your Federal (U.S.) Income Tax Return for the
most recent tax year. The most recent tax year will be 2023, except:
If you submit your MDUFA Small Business Certification
Request for FY 2024 before April 15, 2024, and you have not yet filed
your return for 2023, you may use tax year 2022.
If you submit your MDUFA Small Business Certification
Request for FY 2024 on or after April 15, 2024, and have not yet filed
your 2023 return because you obtained an extension, you may submit your
most recent return filed prior to the extension.
3. For each of your affiliates, either:
If the affiliate is a domestic (U.S.) business, a signed
copy of the affiliate's Federal (U.S.) Income Tax Return for the most
recent tax year, or
If the affiliate is a foreign business and cannot submit a
Federal (U.S.) Income Tax Return, a National Taxing Authority
Certification completed by, and bearing the official seal of, the
National Taxing Authority, if extant, of the country in which the firm
is headquartered. The National Taxing Authority is the foreign
equivalent of the U.S. Internal Revenue Service. This certification
must show the amount of gross receipts or sales for the most recent tax
year, in both U.S. dollars and the local currency of the country, the
exchange rate used in converting the local currency to U.S. dollars,
and the dates of the gross receipts or sales collected. The business
must also submit a statement signed by the head of the business's firm
or by its chief financial officer that the business has submitted
certifications for all of its affiliates, identifying the name of each
affiliate, or that the business has no affiliates.
If your affiliate is headquartered in a country without a
National Taxing Authority, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
4. Once you have completed your Form FDA 3602, print and sign the
form. Mail the completed form and your supporting documentation (copies
of the Federal (U.S.) income tax returns) to Medical Device User Fee
Small Business Certification Request mailing address, which is
available at the following website: https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm577696.htm.
If you need assistance, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
B. Foreign Businesses
If you are a foreign business, and wish to qualify as a small
business for FY 2024, submit the following:
1. A completed MDUFA Foreign Small Business Certification Request
for a Business Headquartered Outside the United States (Form FDA
3602A). Form FDA 3602A is provided in the FDA Forms database: https://www.fda.gov/media/128059/download.
2. A National Taxing Authority Certification, completed by, and
bearing the official seal of, the National Taxing Authority, if extant,
of the country in which the firm is headquartered. This certification
must show the amount of gross receipts or sales for the most recent tax
year, in both U.S. dollars and the local currency of the country, the
exchange rate used in converting the local currency to U.S. dollars,
and the dates of the gross receipts or sales collected.
If your firm is headquartered in a country without a National
Taxing Authority, please contact the Division of Industry and Consumer
Education at 800-638-2041 or 301-796-7100 or email at [email protected].
3. For each of your affiliates, either:
If the affiliate is a domestic (U.S.) business, a signed
copy of the affiliate's Federal (U.S.) Income Tax Return for the most
recent tax year (2022 or later), or
If the affiliate is a foreign business and cannot submit a
Federal (U.S.) Income Tax Return, a National Taxing Authority
Certification completed by, and bearing the official seal of, the
National Taxing Authority, if extant, of the country in which the firm
is headquartered. The National Taxing Authority is the foreign
equivalent of the U.S. Internal Revenue Service. This certification
must show the amount of gross receipts or sales for the most recent tax
year, in both U.S. dollars and the local currency of the country, the
exchange rate used in converting the local currency to U.S. dollars,
and the dates for the gross receipts or sales collected. The business
must also submit a statement signed by the head of the business's firm
or by its chief financial officer that the applicant has submitted
certifications for all of its affiliates, identifying the name of each
affiliate, or that the business has no affiliates.
If your affiliate is headquartered in a country without a
National Taxing Authority, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
4. Once you have completed your Form FDA 3602A, print and sign the
form. Mail the completed form and your supporting documentation,
including the following, to CDRH's Medical Device User Fee Small
Business Certification Request address, which is available at the
following website: https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/ucm577696.htm.
[[Page 48876]]
A copy of the most recent Federal (U.S.) income tax return
for each of your affiliates headquartered in the U.S. and
A copy of an MDUFA Foreign Small Business Certification
Request for each of your foreign affiliates.
If you need assistance, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
VI. Procedures for Paying Application Fees
If your application or submission is subject to a fee and your
payment is received by FDA between October 1, 2023, and September 30,
2024, you must pay the fee in effect for FY 2024. To avoid delay in the
review of your application, you should pay the application fee at the
time you submit your application to FDA. The later of the date that the
application is received in the reviewing center's document room or the
date the U.S. Treasury recognizes the payment determines whether the
fee rates for FY 2023 or FY 2024 apply. FDA must receive the correct
fee at the time that an application is submitted, or the application
will not be accepted for filing or review.
FDA requests that you follow the steps below before submitting a
medical device application subject to a fee to ensure that FDA links
the fee with the correct application. (Note: Do not send your user fee
check to FDA with the application.)
A. Secure a Payment Identification Number (PIN) and Medical Device User
Fee Cover Sheet From FDA Before Submitting Either the Application or
the Payment
Log into the User Fee System at: https://userfees.fda.gov/OA_HTML/mdufmaCAcdLogin.jsp. Complete the Medical Device User Fee cover sheet.
Be sure you choose the correct application submission date range. (Two
choices will be offered until October 1, 2023. One choice is for
applications and fees that will be received on or before September 30,
2023, which are subject to FY 2023 fee rates. A second choice is for
applications and fees received on or after October 1, 2024, which are
subject to FY 2024 fee rates.) After completing data entry, print a
copy of the Medical Device User Fee cover sheet and note the unique PIN
located in the upper right-hand corner of the printed cover sheet.
B. Electronically Transmit a Copy of the Printed Cover Sheet With the
PIN
When you are satisfied that the data on the cover sheet is
accurate, electronically transmit that data to FDA according to
instructions on the screen. Applicants are required to set up a user
account and password to assure data security in the creation and
electronic submission of cover sheets.
C. Submit Payment for the Completed Medical Device User Fee Cover Sheet
1. The preferred payment method is online using electronic check
(Automated Clearing House (ACH) also known as eCheck) or credit card
(Discover, VISA, MasterCard, American Express). FDA has partnered with
the U.S. Department of the Treasury to utilize Pay.gov, a web-based
payment system, for online electronic payment. You may make a payment
via electronic check or credit card after submitting your cover sheet.
Secure electronic payments can be submitted using the User Fees Payment
Portal at https://userfees.fda.gov/pay. Note: Only full payments are
accepted. No partial payments can be made online. Once you search for
your invoice, select ``Pay Now'' to be redirected to Pay.gov.
Electronic payment options are based on the balance due. Payment by
credit card is available for balances that are less than $25,000. If
the balance exceeds this amount, only the ACH option is available.
Payments must be made using U.S. bank accounts as well as U.S. credit
cards.
2. If paying with a paper check:
All paper checks must be in U.S. currency from a U.S. bank
and made payable to the Food and Drug Administration. If needed, FDA's
tax identification number is 53-0196965.
Please write your application's unique PIN (from the upper
right-hand corner of your completed Medical Device User Fee cover
sheet) on your check.
Mail the paper check and a copy of the completed cover
sheet to: Food and Drug Administration, P.O. Box 979033, St. Louis, MO
63197-9000. (Please note that this address is for payments of
application and annual report fees only and is not to be used for
payment of annual establishment registration fees.)
If you prefer to send a check by a courier, the courier may deliver
the check to: U.S. Bank, Attn: Government Lockbox 979033, 1005
Convention Plaza, St. Louis, MO 63101. (Note: This U.S. Bank address is
for courier delivery only. If you have any questions concerning courier
delivery contact U.S. Bank at 314-418-4013. This telephone number is
only for questions about courier delivery.)
3. If paying with a wire transfer:
Please include your application's unique PIN (from the
upper right-hand corner of your completed Medical Device User Fee cover
sheet) in your wire transfer. Without the PIN, your payment may not be
applied to your cover sheet and review of your application may be
delayed.
The originating financial institution may charge a wire
transfer fee. If the financial institution charges a wire transfer fee
it is required that you add that amount to the payment to ensure that
the invoice is paid in full.
Use the following account information when sending a wire transfer:
U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York,
NY 10045, Acct. No. 75060099, Routing No. 021030004, SWIFT: FRNYUS33.
FDA records the official application receipt date as the later of
the following: (1) the date the application was received by the FDA
Document Control Center for the reviewing Center or (2) the date the
U.S. Treasury recognizes the payment.
D. Submit Your Application to FDA With a Copy of the Completed Medical
Device User Fee Cover Sheet
Please submit your application and a copy of the completed Medical
Device User Fee cover sheet to the address located at https://www.fda.gov/cdrhsubmissionaddress.
VII. Procedures for Paying the Annual Fee for Periodic Reporting
You will be invoiced at the end of the quarter in which your PMA
Periodic Report is due. Invoices will be sent based on the details
included on your PMA file. You are responsible for ensuring FDA has
your current billing information, and you may update your contact
information for the PMA by submitting an amendment to the pending PMA
or a supplement to the approved PMA.
1. The preferred payment method is online using electronic check
(ACH also known as eCheck) or credit card (Discover, VISA, MasterCard,
American Express). Secure electronic payments can be submitted using
the User Fees Payment Portal at https://userfees.fda.gov/pay (Note:
Only full payments are accepted. No partial payments can be made
online). Once you search for your invoice, select ``Pay Now'' to be
redirected to Pay.gov. Note that electronic payment options are based
on the balance due. Payment by credit card is available for balances
that are less than $25,000. If the balance exceeds this amount, only
the ACH option is available. Payments must be made using U.S. bank
accounts as well as U.S. credit cards.
[[Page 48877]]
2. If paying with a paper check: The check must be in U.S. currency
from a U.S. bank and made payable to the Food and Drug Administration.
If needed, FDA's tax identification number is 53-0196965.
Please write your invoice number on the check.
Mail the paper check and a copy of the invoice to: Food
and Drug Administration, P.O. Box 979033, St. Louis, MO 63197-9000.
(Please note that this address is for payments of application and
annual report fees only and is not to be used for payment of annual
establishment registration fees.)
To send a check by a courier, the courier must deliver the check
and printed copy of the cover sheet to U.S. Bank, Attn: Government
Lockbox 979033, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This
U.S. Bank address is for courier delivery only. If you have any
questions concerning courier delivery, contact U.S. Bank at 314-418-
4013. This telephone number is only for questions about courier
delivery.)
3. When paying by a wire transfer, it is required that the invoice
number is included; without the invoice number the payment may not be
applied. If the payment amount is not applied, the invoice amount would
be referred to collections. The originating financial institution may
charge a wire transfer fee. If the financial institution charges a wire
transfer fee, it is required that you add that amount to the payment to
ensure that the invoice is paid in full.
Use the following account information when sending a wire transfer:
U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York,
NY 10045, Acct. No. 75060099, Routing No. 021030004, SWIFT: FRNYUS33.
VIII. Procedures for Paying Annual Establishment Registration Fees
To pay the annual establishment registration fee, firms must access
the Device Facility User Fee (DFUF) website at https://userfees.fda.gov/OA_HTML/furls.jsp. (FDA has verified the website
address, but FDA is not responsible for any subsequent changes to the
website address after this document publishes in the Federal Register.)
Create a DFUF order and you will be issued a PIN when you place your
order. After payment has been processed, you will be issued a payment
confirmation number (PCN). You will not be able to register your
establishment if you do not have a PIN and a PCN. An establishment
required to pay an annual establishment registration fee is not legally
registered in FY 2024 until it has completed the steps below to
register and pay any applicable fee (see 21 U.S.C. 379j(f)(2)).
Companies that do not manufacture any product other than a licensed
biologic are required to register in the Blood Establishment
Registration (BER) system. FDA's Center for Biologics Evaluation and
Research (CBER) will send establishment registration fee invoices
annually to these companies.
A. Submit a DFUF Order With a PIN From FDA Before Registering or
Submitting Payment
To submit a DFUF Order, you must create or have previously created
a user account and password for the user fee website listed previously
in this section. After creating a username and password, log into the
Establishment Registration User Fee FY 2024 store. Complete the DFUF
order by entering the number of establishments you are registering that
require payment. When you are satisfied that the information in the
order is accurate, electronically transmit that data to FDA according
to instructions on the screen. Print a copy of the final DFUF order and
note the unique PIN located in the upper right-hand corner of the
printed order.
B. Pay for Your DFUF Order
Unless paying by U.S. credit card, all payments must be in U.S.
currency and drawn on a U.S. bank.
1. If paying by credit card or electronic check (ACH or eCheck):
The DFUF order will include payment information, including details on
how you can pay online using a credit card or electronic check. Follow
the instructions provided to make an electronic payment.
2. If paying with a paper check: The check must be in U.S. currency
and drawn on a U.S. bank, and mailed to: Food and Drug Administration,
P.O. Box 979108, St. Louis, MO 63197-9000. (Note: This address is
different from the address for payments of application and annual
report fees and is to be used only for payment of annual establishment
registration fees.)
If a check is sent by a courier that requests a street address, the
courier can deliver the check to: U.S. Bank, Attn: Government Lockbox
979108, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This U.S.
Bank address is for courier delivery only. If you have any questions
concerning courier delivery, contact U.S. Bank at 314-418-4013. This
telephone number is only for questions about courier delivery.)
Please make sure that both of the following are written on your
check: (1) the FDA post office box number (P.O. Box 979108) and (2) the
PIN that is printed on your order. Include a copy of your printed order
when you mail your check.
3. If paying with a wire transfer: Wire transfers may also be used
to pay annual establishment registration fees. To send a wire transfer,
please read and comply with the following information:
Include your order's unique PIN (in the upper right-hand corner of
your completed DFUF order) in your wire transfer. Without the PIN, your
payment may not be applied to your facility and your registration may
be delayed.
The originating financial institution may charge a wire transfer
fee. If the financial institution charges a wire transfer fee, it is
required that you add that amount to the payment to ensure that the
invoice is paid in full. Use the following account information when
sending a wire transfer: U.S. Dept. of the Treasury, TREAS NYC, 33
Liberty St., New York, NY 10045, Acct. No. 75060099, Routing No.
021030004, SWIFT: FRNYUS33. If needed, FDA's tax identification number
is 53-0196965.
C. Complete the Information Online To Update Your Establishment's
Annual Registration for FY 2024, or To Register a New Establishment for
FY 2024
Go to the Center for Devices and Radiological Health's website at
https://www.fda.gov/medical-devices/how-study-and-market-your-device/device-registration-and-listing and click the ``Access Electronic
Registration'' link on the left side of the page. This opens a new page
with important information about the FDA Unified Registration and
Listing System (FURLS). After reading this information, click on the
``Access Electronic Registration'' link in the middle of the page. This
link takes you to an FDA Industry Systems page with tutorials that
demonstrate how to create a new FURLS user account if your
establishment did not create an account in FY 2023. Manufacturers of
licensed biologics should register in the electronic Blood
Establishment Registration (eBER) system at https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-establishment-registration.
Enter your existing account ID and password to log into FURLS. From
the FURLS/FDA Industry Systems menu, click on the Device Registration
and Listing Module (DRLM) of FURLS button. New establishments will need
to register, and existing establishments will update their annual
registration using choices on the DRLM menu. When you choose to
register or update your annual registration, the system will
[[Page 48878]]
prompt you through the entry of information about your establishment
and your devices. If you have any problems with this process, email:
[email protected] or call 301-796-7400 for assistance. (Note: This
email address and this telephone number are for assistance with
establishment registration only; they are not to be used for questions
related to other aspects of medical device user fees.) Problems with
the eBER system should be directed to https://www.accessdata.fda.gov/scripts/email/cber/bldregcontact.cfm or call 240-402-8360.
D. Enter Your DFUF Order PIN and PCN
After completing your annual or initial registration and device
listing, you will be prompted to enter your DFUF order PIN and PCN,
when applicable. This process does not apply to establishments engaged
only in the manufacture, preparation, propagation, compounding, or
processing of licensed biologic devices. CBER will send invoices for
payment of the establishment registration fee to such establishments.
IX. Small Business Fee Reductions and Fee Waivers
To qualify for reduced fees for small businesses or a small
business fee waiver, please see the requirements for qualification
provided in Section V. How To Qualify as a Small Business for Purposes
of Medical Device Fees. The applicant should submit a Small Business
Certification Request and the supporting materials showing you qualify
as a small business at least 60 days before you send your submission to
FDA. FDA will review your information and determine whether you qualify
as a small business eligible for the reduced fee and/or fee waiver. If
you make a submission before FDA finds that you qualify as a small
business, you must pay the standard (full) fee for that submission.
If you need assistance, please contact the Division of Industry and
Consumer Education at 800-638-2041 or 301-796-7100 or email at
[email protected].
A. Premarket Approval Fee Reduction or Waiver
A small business applicant may request to pay a reduced rate for
premarket approval fees. An applicant may also request a fee waiver for
their first premarket application or premarket report (see 21 U.S.C.
379j(d)).
B. Premarket Notification Submission Fee Reduction
A small business applicant may request to pay a reduced rate for a
premarket notification submission.
C. Annual Establishment Registration Fee
There is no small business waiver for the annual establishment
registration fee; all establishments pay the same fee.
X. Refunds
To qualify for consideration for a refund, a person shall submit to
FDA a written request for a refund not later than 180 days after such
fee is due. FDA has discretion to refund a fee or a portion of the fee.
A determination by FDA concerning a refund shall not be reviewable. For
more information on qualifying and submitting a refund, see 21 U.S.C.
379j(a)(2)(D).
Dated: July 21, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-15919 Filed 7-27-23; 8:45 am]
BILLING CODE 4164-01-P